title: [Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem   cell transplantation in the treatment of drug-resistant Hodgkin disease].
abstract: In 1995-1999, 67 patients with relapsed Hodgkin's disease or refractory to chemotherapy (group A--first relapse, B--primary refractory disease, and C--repeated relapse) received cytoreductive (dexaBEAM, DHAP) therapy followed by high-dose BEAM chemotherapy and autologous bone marrow or blood cell transplantation. Early postoperative transplant-related mortality rate was 4.5%. At day 100, complete remission rates were: group A--95.6%; B--74.1%; and C--76.5%. Survival for all patients was: overall--61.9%; event-free--43.9%; disease-free--46%; and relapse-free survival--49.5%. Such factors as primary refractory disease, age over 30 years and response to cytoreductive therapy had significant influence on overall survival prognosis.
authors.affiliation: Byelorussian Center For Bone Marrow Transplantation, Minsk.
authors.forename: A L
authors.initials: AL
authors.lastname: Uss
authors.forename: V A
authors.initials: VA
authors.lastname: Zmachinskiĭ
authors.forename: N F
authors.initials: NF
authors.lastname: Milanovich
authors.forename: A E
authors.initials: AE
authors.lastname: Skriagin
authors.forename: E V
authors.initials: EV
authors.lastname: Dziuba
authors.forename: S V
authors.initials: SV
authors.lastname: Vlasenkova
authors.forename: N S
authors.initials: NS
authors.lastname: Solov'eva
authors.forename: Z E
authors.initials: ZE
authors.lastname: Batan
authors.forename: P B
authors.initials: PB
authors.lastname: Mitskevich
authors.forename: I L
authors.initials: IL
authors.lastname: Zavgorodniaia
authors.forename: O V
authors.initials: OV
authors.lastname: Aleĭnikova
authors.forename: E A
authors.initials: EA
authors.lastname: Zhavrid
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D008558:Melphalan; D002330:Carmustine
vernacular_title: Mesto vysokodoznoĭ BEAM-terapii i autologichnoĭ transplantatsii  gemopoéticheskikh kletok u bol'nykh khimiorezistentnymi formami  bolezni Khodzhkina.